TLX
TELIX PHARMACEUTICAL ORDINARYTelix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
TLX
TLX
TELIX PHARMACEUTICAL ORDINARY
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 11.72% | — |
| 10 July | 11.85% | — |
| 9 July | 11.88% | — |
| 8 July | 11.91% | — |
| 7 July | 11.87% | — |
| 6 July | 11.90% | — |
| 3 July | 11.67% | — |
| 2 July | 11.99% | — |
| 1 July | 11.90% | — |
Telix Pharmaceutical (TLX) Short Interest Summary
Telix Pharmaceutical (TLX) currently has 11.72% of its shares sold short (39.8 million shares, worth approximately $621.4 million), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes TLX the #7 most shorted stock on the ASX most shorted list. Short interest in TLX is down 0.18% over the past week and down 2.18% over the past month. TLX is part of the Health Care sector on the ASX.
Recent TLX Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 11.72% | 39.8M | $15.99 |
| 10 July 2026 | 11.85% | 40.3M | $16.27 |
| 9 July 2026 | 11.88% | 40.3M | $16.94 |
| 8 July 2026 | 11.91% | 40.4M | $16.58 |
| 7 July 2026 | 11.87% | 40.3M | $16.89 |
| 6 July 2026 | 11.90% | 40.4M | $17.38 |
| 3 July 2026 | 11.67% | 39.6M | $16.88 |
| 2 July 2026 | 11.99% | 40.7M | $17.18 |
| 1 July 2026 | 11.90% | 40.4M | $17.02 |
| 30 June 2026 | 12.03% | 40.8M | $16.58 |
TLX Short Selling — Frequently Asked Questions
What is Telix Pharmaceutical (TLX)'s current short interest?
Telix Pharmaceutical (TLX) currently has a short interest of 11.72% of total shares outstanding. This means 11.72% of TLX's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is TLX heavily shorted on the ASX?
Yes. With 11.72% of its shares sold short, TLX is considered heavily shorted — short interest above 10% is generally regarded as high. TLX is currently ranked #7 among the most shorted stocks on the ASX.
What does short interest mean for TLX investors?
Short interest in TLX shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 11.72%, TLX's high short interest could signal strong bearish sentiment — or potential for a short squeeze if the price rises. See our short squeeze candidates and days to cover analysis for more context.
Where does this TLX short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for TLX.